Disney shareholders rejected an investor proposal to withdraw participation in the Human Rights Campaign's corporate equity index, which rates workplaces on lesbian, gay, bisexual, transgender and queer equality.

Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.

Erie Indemnity (ERIE) could produce exceptional returns because of its solid growth attributes.

We maintain a hold rating on Darden Restaurants, Inc., viewing it as a house position for long-term wealth creation. Darden's fiscal Q3 2025 showed mixed results with a slight revenue miss but a one-penny EPS beat; comparable sales were up 0.7%. DRI continues to benefit from strong performance in LongHorn Steakhouse and Olive Garden, despite weaker fine dining and other business segments.

SWK Holdings Corporation (NASDAQ:SWKH ) Q4 2024 Earnings Conference Call March 20, 2025 10:00 AM ET Company Participants Susan Xu - IR Jody Staggs - President & CEO Adam Rice - CFO Conference Call Participants Operator Greetings. Welcome to the SWK Holdings Fourth Quarter 2024 Conference Call.

- Achieved Approximately $304 Million of Inventory Reduction in the Fiscal Fourth Quarter, Bringing Total Inventory Reduction Since Fiscal Second Quarter Peak to $419 Million -

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your Newmont Corporation (NYSE:NEM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/newmont-corporation-lawsuit-submission-form?prid=137512&wire=1 or contact Joseph E. Levi, Esq.

Kyiv and Dubai, March 20, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator, today provides additional selected financial information about Uklon group (“Uklon”) following its announcement on 19 March 2025 regarding the agreement signed between JSC Kyivstar (“Kyivstar”) and Uklon for Kyivstar to acquire 97% of the shares of Uklon, a leading Ukrainian ride-hailing and delivery platform.

On Thursday, plenty of investors bellied up to the bar to put money into Boston Beer (SAM 2.29%) stock. Best known as the brewer of the Samuel Adams line of suds, the company received a recommendation upgrade from a top U.S. bank tracking its fortunes.

Stock splits are worthless on paper. Your $200 stock splits 4-to-1, and you're handed three extra shares that are now priced at $50 each.

Toll Brothers at Overlook at Lenox will offer stunning, luxury townhomes in a desirable location near downtown Atlanta Toll Brothers at Overlook at Lenox will offer stunning, luxury townhomes in a desirable location near downtown Atlanta

Apple Inc. is undergoing a rare shake-up of its executive ranks to help turn around its AI efforts and the Siri virtual assistant. Apple wants to get AI back on track after months of delays and stumbles.

Apple Inc. is undergoing a rare shake-up of its executive ranks to help turn around its AI efforts and the Siri virtual assistant. Apple wants to get AI back on track after months of delays and stumbles.

U.S. Attorney General Pamela Bondi on Thursday said three people have been charged related to arson incidents at Tesla car dealerships and charging stations. Without specifying the charges, the Justice Department said the individuals each face between five and 20 years in prison.

Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.

Bragg Gaming Group Inc. (NASDAQ:BRAG ) Q4 2024 Results Conference Call March 20, 2025 8:30 AM ET Company Participants Matevz Mazij - Chief Executive Officer Robbie Bressler - Interim Chief Financial Officer Conference Call Participants David McFadgen - Cormark Securities Gianluca Tucci - Haywood Securities Jack Vander Aarde - Maxim Group Operator Good morning, everyone. My name is Regina and thank you for joining the Fourth Quarter and Full Year 2024 Earnings Conference Call for Bragg Gaming Group.

Apple has reportedly made some leadership changes to speed up its development of artificial intelligence (AI) products. The company has put Vision Pro creator Mike Rockwell in charge of its virtual assistant, Siri, and removed Siri from the oversight of AI head John Giannadrea, Bloomberg reported Thursday (March 20), citing unnamed sources.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will.

Nvidia will open a quantum computing research lab in Boston, where it plans to collaborate with scientists from Harvard University and the Massachusetts Institute of Technology, Nvidia CEO Jensen Huang said on Thursday.

Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Metastatic Melanoma R&D. …